Ranibizumab

Drugs

Volumn 67, Issue 8, 2007, Pages 1199-1206

  Blick, Stephanie K A ^a   Keating, Gillian M ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; RANIBIZUMAB; VASCULOTROPIN A;

ARTHRALGIA; BLEPHARITIS; BLURRED VISION; BRONCHITIS; CATARACT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HEMORRHAGE; COUGHING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRY EYE; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; FOREIGN BODY; HUMAN; HYPEREMIA; HYPERTENSION; INJECTION; INTRAOCULAR PRESSURE; LACRIMATION; LENS DISEASE; MAXIMUM TOLERATED DOSE; META ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); OCULAR FIBROSIS; OCULAR PRURITUS; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULOPATHY; RETINA TEAR; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VISUAL DISORDER; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III; HUMANS; MACULAR DEGENERATION;

EID: 34249914760     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767080-00007     Document Type: Review

References (29)

1. Eter N, Krohne TU, Holz FG. New pharmacologic approaches to therapy for age-related macular degeneration. Biodrugs 2006; 20 (3): 167-79
2. Barouch FC, Miller JW. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration. Int Ophthalmol Clin 2004; 44 (3): 23-32
3. Comer GM, Ciulla TA, Criswell MH, et al. Current and future treatment options for nonexudative and exudative age-related macular degeneration. Drugs Aging 2004; 21 (15): 967-92
4. Sorbera LA, Leeson PA, Baýes M. Ranibizumab: treatment of age-related macular degeneration humanized monoclonal anti-VEGF antibody angiogenesis inhibitor. Drugs Future 2003; 28 (6): 541-5
5. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 Dec 30; 351 (27): 2805-16
6. Melnikova I. Wet age-related macular degeneration. Nat Rev Drug Discov 2005 Sep; 4 (9): 711-2
7. Ng EWM, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40 (3): 352-68
8. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006 Sep; 19 (3): 361-72
9. US Food and Drug Administration. Ranibizumab: full prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/ 2006/125156lbl.pdf [Accessed 2007 May 10]
10. Lowe J, Araujo J, Palma M, et al. RhuFab V2 inhibits VEGF-isoforms- stimulated HUVEC proliferation [E-abstract no. 1828]. Invest Ophthalmol Vis Sci 2003; 44
11. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucen-tis™) for neovascular age-related macular degeneration. Ophthalmology 2006 Apr; 113 (4): 623-32
12. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration a phase I/II multicenter, controlled, multidose study [abstract]. Ophthalmology 2006; 113 (4): 642
13. Rosenfeld PJ, Fung AE, Lalwani GA, et al. Visual acuity outcomes following a variable-dosing regimen for ranibizumab (Lucentis™) in neovascular AMD: the PrONTO study [abstract no. 2958]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 2006 Apr 30-May 4; Fort Lauderdale (FL)
14. Korotkin A, Kozak I, Morrison VL, et al. An emerging problem: recurrence of CNV in AMD is common after cessation of 24 month treatment with ranibizumab (Lucentis®) [abstract no. 2961]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 2006 Apr 30-May 4; Fort Lauderdale (FL)
15. Heier JS, Rosenfeld PJ, Antoszyk G, et al. Long-term experience with Lucentis™ (ranibizumab) in patients with neovascular age-related macular degeneration (AMD) [E-abstract no. 1393]. Invest Ophthalmol Vis Sci 2005 May; 46
16. Lalwani G, Fung AE, Michels S, et al. Optical coherence tomography findings in a variable-dosing regimen with ranibizumab (Lucentis™): the PrONTO study [abstract no. 2147]. Annual Meeting of the Association for Research in Vision and Ophthamology; 2006 Apr 30-May 4; Fort Lauderdale (FL)
17. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 Oct 5; 355 (14): 1432-44
18. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 Oct 5; 355 (14): 1419-31
19. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005 Jun; 112 (6): 1048-53
20. Haughney PC, Lowe J, Kearns A, et al. Clinical pharmacokinetics of ranibizumab (Lucentis™) in subjects with AMD [E-abstract no. 1383]. Invest Ophthalmol Vis Sci 2005; 46
21. European Medicines Agency. Ranibizumab (Lucentis): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/lucentis/ H-715-PI-en.pdf [Accessed 2007 Apr 12]
22. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005 Feb; 46 (2): 726-33
23. Schmidt-Erfurth U. The PIER study: twelve month efficacy and safety results from a phase III study of ranibizumab 0.3mg and 0.5mg administered initially monthly and then every 3 months for subfoveal choroidal neovascularization secondary to age-related macular degeneration. PIER study group [abstract no. F1116]. Asian J Ophthalmol 2006; 8 (3 Suppl. 1): 176
24. Brown DM, Yue H, Shams N. Ranibizumab (Lucentis) in ne-ovascular age-related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data [abstract no. 4540/B221]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 2007 May 6-10; Fort Lauderdale (FL)
25. Chang TS, Fine JT, Bressler N, et al. Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis™) [abstract no. 5252]. Annual Meeting of the Association for Research in Vision and Ophthamology; 2006 Apr 30-May 4; Fort Lauderdale (FL)
26. Brown DM, Shapiro H, Schneider S, et al. Subgroup analysis of first-year results of ANCHOR: a phase III, double-masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age-related macular degeneration [abstract no. 2963]. Annual Meeting of the Association for Research in Vision and Ophthamology; 2006 Apr 30-May 4; Fort Lauderdale (FL)
27. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006; 124 (11): 1532-42
28. Genentech, Inc. Dear health care provider letter regarding Lucentis [online]. Available from URL: http://www.fda.gov/medwatch/ safety/2007/ Lucentis_DHCP_01-24-2007.pdf [Accessed 2007 Jan 30]
29. US Food and Drug Administration. 2007 Safety alerts for drugs, biologics, medical devices, and dietary supplements [online]. Available from URL: http://www.fda.gov/medwatch/safety/ 2007/safety07.htm [Accessed 2007 May 4]